Compugen Stock Price, News & Analysis

Compugen Ltd. (NASDAQ: CGEN), a cancer immunotherapy firm, announced that CEO Anat Cohen-Dayag, Ph.D., will join a virtual fireside chat during the JMP Securities Hematology and Oncology Summit on December 6, 2022, at 10:20 am ET. Interested parties can access the live webcast on Compugen's Investor Relations site, with a replay available post-event. The company focuses on developing innovative cancer therapies, including its proprietary product candidates COM701 and COM902, among other early-stage immuno-oncology programs.

Compugen Ltd. (CGEN) announced a $7.5 million milestone payment from AstraZeneca following the initiation of the ARTEMIDE Phase 2 study for AZD2936, a PD-1/TIGIT bispecific antibody. This advancement reinforces confidence in Compugen's COM902 antibody, which is part of their collaboration with AstraZeneca. To date, Compugen has received a total of $18.5 million in payments from AstraZeneca, part of a potential $200 million milestone agreement for the development of bispecific products. The company aims to leverage this opportunity while continuing its focus on its own pipeline of cancer immunotherapies.

Compugen Ltd. (CGEN) reported preliminary clinical data at SITC 2022 highlighting the effectiveness of COM701 combined with nivolumab in metastatic MSS-CRC patients, achieving a 12% response rate. The company plans further clinical trials, including a triple combination with anti-PD-1 and COM902. Additionally, promising data from ovarian cancer cohorts will be presented at ESMO-IO. As of September 30, 2022, Compugen maintains a solid balance sheet with $88 million in cash, expected to last through 2024, despite a net loss of $11.7 million for Q3 2022.

Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, announced its participation in the Stifel 2022 Healthcare Conference on November 15, 2022, at 9:10 am ET. CEO Anat Cohen-Dayag and other management team members will engage in a fireside chat during the event in New York City. A live webcast will be available on Compugen's Investor Relations website, with a replay accessible afterward. The company focuses on innovative drug targets for cancer treatment, with proprietary candidates like COM701 and COM902.

Compugen Ltd. (CGEN) announced promising data on COM701, an anti-PVRIG antibody, demonstrating anti-tumor activity in MSS-CRC patients resistant to usual checkpoint inhibitors. The study highlights significant immune activation within the tumor microenvironment, suggesting COM701's potential to enhance T cell responses when combined with nivolumab. Notable findings include PVRIG's expression on early differentiated stem-like memory T cells, potentially inhibiting T cell expansion in tumors. The data will be elaborated upon during a Q3 earnings call on November 14, 2022, following an oral presentation at SITC on November 11, 2022.

Compugen Ltd. (NASDAQ: CGEN) announced promising preliminary data on its drug COM701 in combination with nivolumab for treating metastatic MSS-CRC patients. The study shows a 12% overall response rate in patients with liver metastases, a significant improvement over historical rates of 0% for similar therapies. Translational data reveal strong immune activation in the tumor microenvironment, indicating a potential breakthrough for this typically non-responsive cancer. The company plans further clinical evaluations and will present detailed findings at the SITC meeting on November 10, 2022.

Compugen Ltd. (NASDAQ: CGEN) received a notification from Nasdaq on October 31, 2022, stating that its ordinary shares failed to maintain the minimum bid price of $1.00 for 30 consecutive business days, as required by Nasdaq Listing Rule 5450(a)(1). The company has a compliance period of 180 days, until May 1, 2023, to regain compliance. If the bid reaches $1.00 for 10 consecutive days before this date, compliance will be confirmed. Failure to comply may lead to delisting, but the company can appeal and possibly receive an additional grace period.

Compugen Ltd. (Nasdaq: CGEN) announced it will release its third quarter 2022 financial results on November 14, 2022, before U.S. market opening. Management will host a conference call at 8:30 AM ET to discuss the results and provide a corporate update, including data to be presented at the Society for Immunotherapy of Cancer meeting from November 8-12, 2022. Compugen focuses on cancer immunotherapy, developing products like COM701 and COM902, and has partnered with Bayer and AstraZeneca on other programs.

Compugen Ltd. (Nasdaq: CGEN) announced new clinical data presentations for COM701 and its combinations at the ESMO-IO congress from December 7-9, 2022, in Geneva. Key presentations include findings on the triple blockade of the DNAM-axis in platinum-resistant ovarian cancer, and COM701's use in metastatic NSCLC patients previously treated with PD-1/PD-L1 inhibitors. These results aim to highlight the antitumor activity of Compugen's therapeutic candidates, advancing their immuno-oncology pipeline.